ROCKET PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.42 USD | +1.43% |
|
+0.30% | -21.82% |
| May. 10 | UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating | MT |
| May. 10 | Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise | MT |
Presenter SpeechJason Russell (Analysts)Okay. Great. Thanks, everyone, for joining. To the res...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.
Calendar
2024-05-15
- BofA Securities Health Care Conference
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
23.09
USD
Average target price
50.08
USD
Spread / Average Target
+116.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.82% | 2.1B | |
| +5.12% | 111B | |
| +12.32% | 105B | |
| -12.76% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.96% | 16.96B | |
| +4.66% | 13.7B | |
| +36.52% | 12.45B |
- Stock Market
- Equities
- RCKT Stock
- News Rocket Pharmaceuticals, Inc.
- Transcript : Rocket Pharmaceuticals, Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-13-2022 03
